Pharmafile Logo

Latest wave of Therapy Watch IBD to run this month

November 23, 2016 | IBD, autoimmune disease, therapy watch 

The IBD syndicated market tracker is part of our large auto-immune portfolio

This month, Therapy Watch IBD will be running in the 5 EU markets of France, Germany, Italy, Spain and the UK. A panel of 200 gastroenterologists will report in 10 IBD patient record forms each quarter (5 Crohn’s disease and 5 ulcerative colitis), to monitor the evolving IBD treatment landscape.

http://www.researchpartnership.com/news/2016/08/latest-wave-of-therapy-watch-ibd-to-run-this-month/

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Free Thinking: Behavioural economics

Our Free Thinking white paper asks, does behavioural economic theory have a role to play in pharmaceutical market research?

Article: The Colombia Conundrum

Published in eye for pharma 30 January by Marc Yates

Ageing in China: The Implications for Healthcare

Published in eye for pharma 12 December by Marc Yates

Exploring MINT: Part 4 - Turkey

In the fourth and final of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in...

Getting to grips with Russia’s healthcare market

As a non-Russian, trying to understand the complexities of the multiple overlapping levels of Russia’s healthcare system can be baffling at times. Information is often inaccessible or data simply doesn't...

Exploring MINT: Part 3 - Nigeria

In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria.

Exploring MINT: Part 2 - Indonesia

In the second of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Indonesia, with...

Free Thinking: Leveraging the ASEAN Market

If you can only research one ASEAN market, which one do you choose?Our Free Thinking paper investigates the opportunities for pharma in ASEAN and outlines the factors you need to...

Free Thinking: Biosimilars: Friend or foe to healthcare?

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.